Regeneron Pharmaceuticals, Inc.
Methods of Treating Multiple Myeloma with Bispecific Anti-BCMA x Anti-CD3 Antibodies

Abstract:

B-cell maturation antigen (BCMA) is expressed on malignant plasma cells. The present invention provides methods for treating multiple myeloma using bispecific antibodies (bsAbs) that bind to both BCMA and CD3 and activate T cells via the CD3 complex in the presence of BCMA-expressing tumor cells. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing BCMA.